Kamari Koonce

Kamari Koonce

Associate
Baker & McKenzie LLP

Biography

Kamari Koonce is an associate in Baker McKenzie’s Global Transactional Practice Group in Chicago. While in law school, Kamari served as editor-in-chief of the Emory Corporate Governance and Accountability Review. She earned her Juris Doctor with a certificate of specialization in Transactional Law and Skills.

Practice Focus

Kamari focuses her practice on domestic and cross-border mergers and acquisitions and private equity transactions. She has represented public and private companies on both the buy side and sell side in acquisitions, divestitures, and mergers, including public company transactions in the life sciences and technology sectors.

Kamari assists clients at each stage of a transaction, including due diligence, drafting transaction documents, closing, and post-closing matters. She has managed due diligence reviews for acquisition targets in the technology, software, life sciences, and industrials sectors.

Kamari also advises investment fund sponsors and institutional investors on fund investments and real estate investment structures.

Representative Legal Matters

Since joining the Firm, Kamari has worked on the following selected matters, representing:

  • Servier, an independent international pharmaceutical group governed by a foundation, in its acquisition of Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN), a commercial-stage biopharmaceutical company developing targeted therapies for life-threatening diseases, for approximately USD 2.5 billion through a cash tender offer and second-step merger.
  • LumApps, a prominent leader in intranet platforms, on legal due diligence matters in connection with its merger agreement with Beekeeper. The combination created the first AI-powered Employee Hub, with a combined valuation exceeding USD 1 billion, more than 7 million users, and approximately USD 150 million in recurring revenues.
  • Synaptics Incorporated (NASDAQ: SYNA) in its agreement to be acquired by onsemi (NASDAQ: ON) in an all-stock transaction valuing Synaptics at an enterprise value of approximately USD 7 billion.
  • H. Lundbeck A/S, a global pharmaceutical company focused on treatments for brain diseases, in its acquisition of Longboard Pharmaceuticals, Inc., a company focused on developing medicines for neurological diseases, in a transaction valued at USD 2.6 billion in cash.
  • A seller in the sale of its wholesale distribution business through an asset purchase, including sell-side diligence and management.
  • A purchaser in the acquisition of a company through a membership interest purchase, including management of post-closing obligations.
  • A sovereign wealth fund in capital commitments totaling more than USD 1 billion to TPG, Warburg Pincus, Jadian Capital, and ISQ Global.
  • A real estate investment manager with USD 84.9 billion in assets under management in Delaware statutory trust formations and private offerings totaling approximately USD 415 million.
  • A US-based alternative asset manager with USD 284 billion in assets under management in Delaware statutory trust formations and private offerings totaling approximately USD 247 million.
  • A US-based real estate investment firm with USD 1.3 billion in assets under management in the formation of a series LLC to provide acquisition financing to affiliated fund portfolio companies targeting real estate assets.

    Admissions

    • Georgia~United States (2026)
    • District of Columbia~United States (2025)
    • Illinois~United States (2023)

    Education

    • Emory University School of Law (J.D., Transactional Law and Skills Certificate) (2023)

    Languages

    • English

    Previous Offices

    • Washington D.C.
    • Author, "The Race to Net Zero: How ESG Investors Are Driving Corporations to Ethically Lower Greenhouse Gas Emissions," Environmental Law and Policy Journal at UC Davis School of Law, May 2023